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Retinal vasoproliferative tumors (VPT) are uncommon benign vascular tumors. They mostly occur in
healthy patients, but may be associated with other chorioretinal diseases. Here we report four patients
with VPT at a referral center from 2006 to 2015. Three patients denied any past history and one had a
history of retinal detachment surgery. VPT-related complications included epiretinal membrane (ERM)
(n¼ 2), cystoids macular edema (n¼ 1), and lamellar hole combined with dense cataract, rigid anterior
capsule and vitreous opacity (n¼ 1). Treatments for VPT and comorbidities included vitrectomy (VT) and
membrane peeling with tumor resection (n¼ 2), a combined treatment of photodynamic therapy (PDT)
and intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) (n¼ 2). Tumor
shrinkage was achieved in both patients treated with PDT and IVI of anti-VEGF injection. The other two
patients with ERMwere successfully treated with VT and tumor resection. Visual acuity improved at least
two lines in three patients, and one patient had decreased vision due to cataract formation after VT.
Pathology of the resected tumor in one case revealed massive gliosis with positive stain of vascular
endothelial cells and glial ﬁbrillary acidic protein stain. Yet the peeled membrane was acellular. Possible
beneﬁcial treatments for VPT and comorbidities include PDT combined with IVI of anti-VEGF, or VT and
membrane peeling with tumor resection.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Retinal vasoproliferative tumors (VPT) are rare, unilateral and
benign retinal vascular tumors. They are yellowish-red tumors, and
are mostly located on the inferotemporal peripheral retina. Unlike
the retinal hemangioblastoma, VPT rarely have dilated and
inﬂamed feeder or drainage vessels, and they demonstrate a
paucity of microvessels yet a preponderance of gliosis.1
VPT mostly occur in middle-aged patients who are healthy
(primary VPT), or they may be associated with other chorioretinal
diseases such as uveitis, retinitis pigmentosa, and Coats’ disease.
They may also occur after retinal detachment surgery (secondary
VPT).2e6 Most patients suffer from visual symptoms that are sec-
ondary to leakage and inﬂammation of this peripheral vascular
tumor, such as decreased vision, ﬂoater, distortion, or photopsia.7,8
Without dilating the pupil and checking the peripheral retina, theof interest.
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iety of Taiwan. Published by ElseviVPT might be missed. Visual acuity (VA) varied from light percep-
tion to 6/6, depending on the complications of VPT.7,8 The clinical
course was generally insidious and slow but exudative retinal
detachmentwithmacula involvement or neovascular glaucoma has
been reported.8,9
To the best of our knowledge, only one case of VPT has been
orally presented at the annual meeting of the Taiwan Ophthal-
mology Society in 2013 by Chu &Wang, and another possible case
of VPT has been published in one report.10 In this study, we report
four cases of VPT. Two patients had more than 8 years of follow-up.
The clinical presentation, treatment and outcome, as well as the
histopathology of the tumor are described.2. Case reports
Four patients with VPT were recruited following a chart review
from 2006 to 2015. Three healthy females with an average age of 49
years had primary VPT without prior ocular history or surgery. One
84-year-old male had a history of retinal detachment surgery.
Initial best-corrected VA was less than 6/12 in all patients (average
Snellen acuity of 6/24). After fundus examination, two patients had
a yellowish-red tumor at the temporal lower periphery (primaryer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Color fundus of Case 1 (A) at presentation; (B) rapid and dense ERM occured
after 3 weeks; (C) VPT with retinal hemorrhage and pigmented retina change; and (D)
disapperance of tumor with chorioretinal scar after VT, membrane peeling, and tumor
resection. ERM¼ epiretinal membrane; VPT¼ vasoproliferative tumor;
VT¼ vitrectomy.
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the temporal upper periphery (secondary VPT) (Table 1).
2.1. Case 1
In 2006, a 41-year-old female presented with blurred vision in
the left eye. The rapid and dense epiretinal membrane (ERM) was
noted just 3 weeks after her ﬁrst visit (Figure 1). VA also dropped
from 6/7.5 to 6/60. Due to a progressive thickening of the ERM and
worsening VA, we promptly performed vitrectomy (VT), membrane
peeling, and external tumor resection. VA improved to 6/8.6 in 6
months after surgery and this was maintained for 6 years until the
last visit.
2.2. Case 2
This was an 84-year-old male with a history of retinal detach-
ment surgery and cataract surgery 3 years previously. The tumor
was located at the border of an old chorioretinal scar at the tem-
poral upper periphery on the left eye (Figure 2). Cystoid macular
edema was found on optical coherence tomography (OCT). He
received three intravitreal injections (IVI) of bevacizumab and two
treatments of photodynamic therapy (PDT). As a result, the tumor
shrank and the macular was ﬂat. VA improved from 6/15 to 6/10
and was maintained for 6 years.
2.3. Case 3
Case 3 was a 58-year-old female with VA of 6/30 in her right eye.
A slit-lamp examination showed a dense cataract. Indirect
ophthalmoscopy revealed VPT with lipid exudate, vitreous opacity
with ﬁbrin sheet, and lamellar hole (Figure 3). She also received IVI
of ranibizumab (twice) and PDT (once). We then performed
phacoemulsiﬁcation and intraocular lens implantation 9 months
after the PDT. A very rigid and resistant anterior capsule was found
during the cataract surgery. After 1 month, severe anterior capsule
contraction was noted. Following neodymium-doped yttrium
aluminum garnet (Nd:YAG, Lightex Inc) laser anterior capsulotomy,
the VA improved to 6/10.
2.4. Case 4
A 48-year-old female presented with blurred vision of the right
eye. VPT and ERM were diagnosed, and two treatments of IVI ofTable 1
Demographic and clinical data of the four patients with VPT.
1 2
Age 41 84
Gender F M
Eye OS OS
Location Inferotemporal Superotemporal
Previous history Nil RD surgery
Initial VA 6/60 6/15
Complication ERM Cystoid macular edem
Treatment VTþMPþ tumor resection, Phaco-IOL PDTþ IVI of bevacizum
Follow-up time 9 years 8 years
Final VA 6/8.6 6/10
ERM¼ epiretinal membrane; IVI¼ intravitreal injection; MP¼membrane peeling; PD
implantation; RD¼ retinal detachment; VA¼ visual acuity; VT¼ vitrectomy.ranibizumab and one of PDT were carried out before the planned
surgery in order to shrink the tumor. Six weeks after PDT, we
performed VT, membrane peeling, and tumor resection (Figure 4).
To avoid intraoperative bleeding, under general anesthesia, systolic
blood pressure was controlled between 80e100 mmHg during the
procedure of tumor resection. The tumor was located by indirect
ophthalmoscopy and a 6 4 mm sclera lamellar ﬂap was made.
Diathermy was carried out on the margin of the exposed choroid
under the deep scleral ﬂap with careful cauterization to reduce
bleeding, followed by resection of the choroid and the tumor with
scissors, along with the deep scleral ﬂap. The superﬁcial scleral ﬂap
was covered back and sutured, with additional transscleral cryo-
therapy along the scleral ﬂap. VT was then performed. During the
VT, no posterior vitreous detachment (PVD) was found and the ERM
was adherent to the posterior hyaloid membrane. After carefully
isolating and removing the ERM, the underlying internal limiting
membrane (ILM) was found to be intact and was subsequentlyCase
3 4
58 48
F F
OD OD
Inferotemporal Inferonasal
Nil Nil
6/30 6/12
a Lamellar hole, dense cataract with
rigid anterior capsule and vitreous opacity
ERM
ab PDTþ IVI of ranibizumab, Phaco-IOL PDTþ IVI of ranibizumab,
VTþMPþ tumor resection
10 months 7 months
6/10 6/15
T¼ photodynamic therapy; Phaco-IOL¼ phacoemulsiﬁcation and intraocular lens
Fig. 2. Color fundus of Case 2 (A) at presentation; (B) 1.5 years after ﬁrst IVI of bevacizumab; (C) 1 month after second IVI of bevacizumab and ﬁrst PDT; and (D) 4 months after third
IVI of bevacizumab and second PDT. IVI¼ intravitreal injection; PDT¼ photodynamic therapy.
Fig. 3. Color fundus of Case 3 (A) at presentation; and (B) 9 months after ﬁrst PDT and
second IVI of ranibizumab. IVI¼ intravitreal injection; PDT¼ photodynamic therapy.
Fig. 4. Color fundus of Case 4 (A) at presentation with ERM; (B) tumor at nasal lower peri
peeling, and tumor resection showed ﬂat macular; (E) laser scar and absence of tumor; an
made to cover the tumor (blue dot); (H) followed by diathermy on the margin of the deep
scleral ﬂap. (J) Tumor (arrow) exposure and resection; (K) peeling of ERM, after VT; and (L)
Massive gliosis in H&E stain of the resected tumor. (N) Proliferated endothelial cells of bloo
(P) The pathology of the peeled membrane showed scant cells. (Q) The pathology of ILM re
glial cells and few ﬁbroblasts. ERM¼ epiretinal membrane; GFAP¼ glial ﬁbrillary acid
VT¼ vitrectomy.
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shallow retinal detachment alongside the resected tumor. Pathol-
ogy of the resected tumor revealed massive gliosis with a positive
CD31 stain of vascular endothelium, and a positive of glial ﬁbrillary
acidic protein (GFAP). Pathology of the peeled membrane showed
acellular membrane without glial cells or ﬁbroblasts. The post-
operative vitreous hemorrhage cleared up in 2 months following
two treatments of ﬂuid gas exchange. The VA of the ﬁnal follow up
4 months later was 6/15 due to cataract.
Table 1 summarizes the demographic and clinical data of the
four cases with VPT. The associated complications included ERM
(n¼ 2), lamellar hole (n¼ 1), cystoid macular edema (n¼ 1), and
dense cataract with rigid anterior capsule and vitreous opacity
(n¼ 1). Treatments included VT andmembrane peeling with tumor
resection (n¼ 2), combined therapy of PDT and IVI of anti-vascular
endothelial growth factor (VEGF) (n¼ 2). Tumor shrinkage was
achieved in all patients treated with PDT and IVI of anti-VEGF. VA
improved at least two lines in three patients, and one had
decreased vision (6/12 to 6/15) due to cataract formation after VT
(Case 4).phery; and (C) retinal edema with ERM in OCT. (D) Color fundus after VT, membrane
d (F) normalized macular thickness in OCT. (G) A 6 4 mm sclera lamellar ﬂap was
scleral ﬂap; and (I) diathermy on the margin of the exposed choroid along with the
endolaser to conﬁne the shallow retinal detachment alongside the resected tumor. (M)
d vessels in CD31 stain. (O) Highly elongated ﬁbrous astrocytes (arrows) in GFAP stain.
vealed hypocellular membrane with homogeneous cell distribution, low cellularity of
ic protein; ILM¼ internal lifting membrane; OCT¼optical coherence tomography;
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We presented four cases with VPT which was the largest study
of VPT reported in Taiwan. We found that the most unique feature
was rapid progression of ERM and decreased VA.
Idiopathic ERM is mostly associated with increased age and
PVD.11 VA can remain stable for years, compared to VPT-related
ERM with rapidly worsening VA. Previous reports of VPT compli-
cated with ERM showed a mean of 5 months duration between the
time of developing visual symptoms and the diagnosis of VPT.12 In
our study, the two cases with complicated ERM (Case 1, Case 4)
were younger and had visual loss due to rapid ERM formation in an
average of 5 weeks (4 weeks, and 6 weeks). In addition, there was
no PVD during VT in these two cases. The histopathology of the
ERM in Case 4 showed minimal cellularity, which was not common
in idiopathic ERM where glial cells and myoﬁbroblasts prolifer-
ated.13 The peeled ILM, however, showed greater cellularity than
the overlying ERM. We presumed that the mainly collagen ﬁbers of
the ERM was actually the localized contracture of the posterior
hyaloid membrane. It was unknown how the VPT can induce the
contracture of collagen ﬁbers without cellular reaction.
VPT-related complications of the anterior segment were rarely
reported. The most common anterior segment complication in eyes
with VPT was glaucoma.7 One patient had complicated neovascular
glaucoma due to peripheral anterior synechia and neo-
vascularization in the iris and angle.9 After receiving VT and tumor
resection, the intraocular pressure was normalized.9 Another two
cases with ocular hypertension were treated with topical anti-
glaucoma medications and Ahmed valve implantation respec-
tively.7 In Case 3 there was posterior segment ﬁndings of retinal
lipid exudate, ﬁbrinous reaction and lamellar hole. Dense and rigid
anterior capsule was also found during cataract surgery. Rapid
anterior capsule phimosis developed within 3 weeks after cataract
extraction. The ﬁbrous contracture of the lens capsule was similar
to the development of ERM formation in Cases 1 and 4. It will be
interesting to examine the removed lens capsule to see if there is
any difference between the capsule and removed ERM.
The current managements for VPT include observation, cryo-
therapy, laser photocoagulation, PDT, plaquebrachytherapy, and IVI of
anti-VEGF or dexamethasone implant. Photocoagulation alone does
not change the tumor lesion nor improve subretinal ﬂuid on OCT.14,15
IVI of bevacizumab alone can improve VA, but without signiﬁcant
difference and does not last long.16,17 PDT alone shows successful re-
gressions of tumors. 14,18 However, intraretinal and subretinal exuda-
tion may increase because of the inﬂammation and vaso-occlusive
effects for PDT. 14,18 In Case 2, the tumor remained the same size after
one dose of IVI. After two sessions of combined PDT plus IVI of bev-
acizumab, within 2 months the tumor regressed for 6 years. Combi-
nation therapy, such as that for the small retinal hemangioblastoma in
von Hippel-Lindau disease, is probably one of the best treatment
choices for VPT.19 Two of our cases had VT and tumor resection to
remove the tumor and ERMat the same time. One had PDT plus IVI of
ranibizumabbefore the surgery in attempt to decrease the tumor size.
Histopathology of the VPT in Case 4 reveals elongated, GFAP-
positive spindle-shaped glial cells, and positive CD31/CD34 of the
vascular component without mitotic appearance, which was
similar to previous reports.1,8 VPT is also called reactive retinal
astrocytic tumor because of the small number of microvessels with
a very low proliferation index, such as Ki67 staining (cell replication
indicator).1 However, they still provide some capacity to damage
retina or other intraocular tissue due to secondary exudation or
inﬂammation. The acellular ﬁbrous membrane in our ERM spec-
imen and the lens capsule thickening in another case might indi-
cate that the VPT can probably actively secrete factors to enhance
ﬁbrous tissue proliferation.The VPT shares similar fundus appearance with other retinal
vascular tumors, such as retinal hemangioblastomaswith or without
von Hippel-Lindau disease. Unlike the VPT, hemangioblastomas
usually occur at a younger age (10e40years),withprominent feeding
and draining vessels, and are bilaterally involved with multiple lo-
cations. Moreover, retinal hemangioblastoma rarely have the
complication of ERM. Patient history of renal cell carcinoma, central
nervous system hemangiomas, and other tumors may also provide
additional information for suspected von Hippel-Lindau disease.20
There are several limitations in this article, including the limited
number of cases, absence of tumor size measurement, and lack of
histopathology of the lens capsule specimen.
In summary, the most common complication of VPT in our study
was the rapid development of ERM.We also found one patient with
anterior segment complication. Combination therapy with PDT and
IVI of anti-VEGF provided long-term tumor regression and dry
macula. VT with membrane peeling and external tumor resection
could be another treatment of choice to remove the ERM and tumor
together. The clinical spectrum and histopathology in our study
suggest that VPT can secrete some factors enhancing the ﬁbrous
contracture without many cellular reactions. Correct diagnosis and
appropriate treatments are important to halt the progression and
complications of VPT.References
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